Ubs Asset Management Americas Inc Verve Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 183,610 shares of VERV stock, worth $2.04 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
183,610
Previous 133,566
37.47%
Holding current value
$2.04 Million
Previous $610,000
237.87%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding VERV
# of Institutions
195Shares Held
72.2MCall Options Held
452KPut Options Held
2.96M-
Alphabet Inc. Mountain View, CA12.2MShares$135 Million8.86% of portfolio
-
Pentwater Capital Management LP Naples, FL6.72MShares$74.8 Million0.5% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.19MShares$46.7 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4.1MShares$45.6 Million6.45% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $667M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...